August 9, 2018 06:49 AM EDT
Financing
China

Tout­ing its man­u­fac­tur­ing strengths, Tot Bio­pharm rais­es $102M mega-round to ramp up can­cer R&D

Amber Tong

The mega-round club of Chi­na’s on­col­o­gy drug­mak­ers is just get­ting start­ed.

In the lat­est, Suzhou-based Tot Bio­pharm closed $102 mil­lion in Se­ries B cash to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times